跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,043 条关于
“ArriVent Biopharma”
全部
2,043
临床试验
47
药物
398
机构
203
资讯
1,395
去年
ArriVent BioPharma Raises $75 Million to Advance Firmonertinib and Cancer Pipeline
去年
ArriVent Biopharma Secures Strong Financial Position with $266.5M Cash Reserve Following Successful IPO
12个月前
ArriVent BioPharma Appoints Brent Rice as Chief Commercial Officer to Lead Firmonertinib Commercialization
去年
ArriVent BioPharma Expands Portfolio with Novel ADC for GI Cancers, Reports Strong NSCLC Trial Results
9个月前
ArriVent Initiates Pivotal Phase 3 ALPACCA Trial for Firmonertinib in EGFR PACC Mutant NSCLC
上个月
ArriVent Advances Firmonertinib Toward Pivotal EGFR Exon 20 NSCLC Data as ADC Pipeline Progresses
2年前
Metagenomi Aims for $87M IPO to Advance Novel Gene Editing Platform
3个月前
EGFR Inhibitors Market Poised for 7.9% CAGR Growth Through 2036, Driven by Next-Generation TKIs, ADCs, and Bispecific Antibodies
10个月前
EGFR-Mutated NSCLC Pipeline Expands with 30+ Therapies as FDA Approves Dato-DXd and J&J Combination Shows Survival Benefit
2年前
Immix Biopharma's NXC-201 Shows Promise as Outpatient CAR-T Therapy in Amyloidosis and Multiple Myeloma
第 1 页,共 140 页
上一页
下一页